Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068540 | 0.89 | CYP3A4 (0.39) | TSHRALDH1A1CYP3A4TDP1OPRM1 | |
| SCHEMBL7067524 | 0.82 | HTT (0.41) | KDM4EHTTMEN1KMT2ATSHR | |
| SCHEMBL18216549 | 0.80 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| SCHEMBL18213635 | 0.80 | HTR1A (0.42) | OPRM1 | |
| SCHEMBL5039661 | 0.80 | HTR1A (0.42) | OPRM1 | |
| SCHEMBL23637367 | 0.80 | CARM1 (0.37) | CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL8723759 | 0.78 | SIGMAR1 (0.42) | KDM4EHTTMEN1KMT2ATSHR | |
| SCHEMBL8770815 | 0.78 | LCK (0.36) | — | |
| SCHEMBL505809 | 0.78 | TDP1 (0.41) | TSHRALDH1A1CYP3A4TDP1POLB | |
| SCHEMBL9619532 | 0.78 | SIGMAR1 (0.44) | KDM4EHTTMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016147-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-8048982-B2 | Method for producing aromatic compound polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2241548-A1 | Vanadium di-nuclear complex | Sumitomo Chemical Company, Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241547-A1 | Method for producing aromatic compound polymer | Sumitomo Chemical Company, Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090018309-A1 | Method for Producing Aromatic Compound Polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1767560-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018309-A1 | Method for Producing Aromatic Compound Polymer | PAH, MAOA, AHR | KDM4E 1477/4885HTT 1976/4885MEN1 4081/4885 |
| US-20120016147-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER | PAH, MAOA, AHR | KDM4E 1516/4885HTT 2001/4885MEN1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.